Stonepine Capital Management LLC lifted its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 266.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 110,000 shares of the company's stock after acquiring an additional 80,000 shares during the period. Stonepine Capital Management LLC owned approximately 0.30% of iTeos Therapeutics worth $845,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in ITOS. JPMorgan Chase & Co. increased its position in shares of iTeos Therapeutics by 1.2% in the third quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company's stock worth $4,771,000 after acquiring an additional 5,368 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new position in iTeos Therapeutics during the 4th quarter worth $96,000. SG Americas Securities LLC grew its holdings in iTeos Therapeutics by 12.2% during the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company's stock worth $106,000 after acquiring an additional 1,508 shares in the last quarter. Empowered Funds LLC grew its holdings in iTeos Therapeutics by 5.0% during the 4th quarter. Empowered Funds LLC now owns 69,072 shares of the company's stock worth $530,000 after acquiring an additional 3,305 shares in the last quarter. Finally, Peapod Lane Capital LLC acquired a new position in iTeos Therapeutics during the 4th quarter worth $836,000. Institutional investors and hedge funds own 97.16% of the company's stock.
Insider Transactions at iTeos Therapeutics
In other iTeos Therapeutics news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the company's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the completion of the sale, the insider now directly owns 3,452,797 shares of the company's stock, valued at approximately $27,829,543.82. This represents a 23.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of iTeos Therapeutics stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the completion of the transaction, the insider now directly owns 2,108,594 shares in the company, valued at approximately $16,995,267.64. This trade represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 12.50% of the company's stock.
iTeos Therapeutics Stock Performance
Shares of ITOS stock traded down $0.13 during midday trading on Wednesday, reaching $8.22. 1,972,000 shares of the company were exchanged, compared to its average volume of 561,932. iTeos Therapeutics, Inc. has a 12 month low of $4.80 and a 12 month high of $18.30. The company has a market cap of $314.61 million, a P/E ratio of -2.61 and a beta of 1.39. The company's 50 day moving average price is $6.65 and its two-hundred day moving average price is $7.40.
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, topping analysts' consensus estimates of ($0.94) by $0.14. As a group, sell-side analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.
Analysts Set New Price Targets
ITOS has been the subject of several recent analyst reports. Leerink Partnrs lowered shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 14th. Raymond James set a $12.00 price objective on shares of iTeos Therapeutics in a report on Wednesday, May 14th. HC Wainwright lowered shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, May 14th. Wells Fargo & Company reissued an "overweight" rating and set a $13.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Finally, Leerink Partners restated a "market perform" rating and set a $9.00 price objective (down from $47.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $17.86.
Read Our Latest Research Report on ITOS
iTeos Therapeutics Profile
(
Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Read More
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
